OMER News and Press, Omeros Corporation From 11/27/23

2023-11-27 01:18:10 ET Summary Omeros Corporation focuses on small-molecule and antibody drugs for common disorders and rare diseases. The company has prioritized the resubmission of its BLA for Narsoplimab for TA-TMA treatment and is advancing Phase-3 clinical trials for MASP-3 i...

2023-11-17 05:55:00 ET Summary Biotech sector faces challenges including higher interest rates, inflation, regulatory pressures, and a post-COVID slump. Short interest remains high for some pharmaceutical companies, indicating bearish sentiment. Exchange-traded funds in the bi...

2023-11-10 10:32:09 ET Omeros Corporation (OMER) Q3 2023 Earnings Conference Call November 09, 2023 04:30 PM ET Company Participants Jennifer Williams - Investor Relations Greg Demopulos - Chairman & Chief Executive Officer Mike Jacobsen - Chief Accounting Of...

2023-11-09 16:27:39 ET More on Omeros Omeros: Where Medical Hopes Tangle With Fiscal Ropes Omeros: Betting Big On Narsoplimab, We Are Still A Buyer Omeros Q3 2023 Earnings Preview Omeros stock plunges 48% on failed Phase 3 study for narsoplimab Seekin...

– Conference Call Today at 1:30 p.m. ET Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic dis...

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

Omeros Corporation (OMER) is expected to report $-0.62 for Q3 2023

Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter ended September 30, 2023, on Thursday, November 9, 2023, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time ...

-- Poster Presentation Slated for Upcoming Annual Meeting of the American Society of Hematology -- Omeros Corporation (Nasdaq: OMER) today announced online publication of a report detailing treatment with narsoplimab of 15 adult and pediatric patients with hematopoietic stem cell transp...

Omeros Corporation (Nasdaq: OMER) today announced that Andreas Grauer, M.D., has been named Omeros’ chief medical officer. In his new role, Dr. Grauer will be responsible for guiding all clinical activities globally for the company, including clinical development and operations, medical af...